Literature DB >> 26476220

Natural History, Prognosis, and Socioeconomic Aspects of Psoriatic Arthritis.

Philip S Helliwell1, Eric M Ruderman2.   

Abstract

Although early reports suggested psoriatic arthritis was, with the exception of arthritis mutilans, a relatively mild arthritis, later studies have challenged this view. The burden of skin disease adds to disability and impaired quality of life. Patients in secondary care manifest increased morbidity and mortality, mainly owing to cardiovascular disease. A subset of patients, primarily men with oligoarticular disease, demonstrates low levels of joint involvement without disability. The socioeconomic impact of the disease is significant. We require more information on the impact of early diagnosis and treatment on outcome, according to phenotype, to guide policy.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Comorbidities; Disability; Natural history; Prognosis; Psoriasis; Psoriatic arthritis; Quality of life; Work

Mesh:

Year:  2015        PMID: 26476220     DOI: 10.1016/j.rdc.2015.07.004

Source DB:  PubMed          Journal:  Rheum Dis Clin North Am        ISSN: 0889-857X            Impact factor:   2.670


  8 in total

Review 1.  Multidisciplinary Management of Psoriatic Arthritis: The Benefits of a Comprehensive Approach.

Authors:  Elisa Visalli; Natascia Crispino; Rosario Foti
Journal:  Adv Ther       Date:  2019-02-25       Impact factor: 3.845

Review 2.  Comorbidity in Adult Psoriasis: Considerations for the Clinician.

Authors:  Christine Daugaard; Lars Iversen; Kasper Fjellhaugen Hjuler
Journal:  Psoriasis (Auckl)       Date:  2022-06-10

Review 3.  Residual Disease Associated with Suboptimal Treatment Response in Patients with Psoriatic Arthritis: A Systematic Review of Real-World Evidence.

Authors:  Laura C Coates; Maarten de Wit; Amy Buchanan-Hughes; Maartje Smulders; Anna Sheahan; Alexis R Ogdie
Journal:  Rheumatol Ther       Date:  2022-04-12

Review 4.  Recent advances in understanding and managing psoriatic arthritis.

Authors:  Dafna D Gladman
Journal:  F1000Res       Date:  2016-11-16

5.  Income disparities in healthcare use remain after controlling for healthcare need: evidence from Swedish register data on psoriasis and psoriatic arthritis.

Authors:  Sofia Löfvendahl; Anna Jöud; Ingemar F Petersson; Elke Theander; Åke Svensson; Katarina Steen Carlsson
Journal:  Eur J Health Econ       Date:  2017-05-19

6.  Evaluation of a Genetic Risk Score for Diagnosis of Psoriatic Arthritis.

Authors:  Mary Patricia Smith; Karen Ly; Quinn Thibodeaux; Kristen Beck; Eric Yang; Isabelle Sanchez; Joanne Nititham; Tina Bhutani; Wilson Liao
Journal:  J Psoriasis Psoriatic Arthritis       Date:  2020-03-04

7.  Genetic signature to provide robust risk assessment of psoriatic arthritis development in psoriasis patients.

Authors:  Matthew T Patrick; Philip E Stuart; Kalpana Raja; Johann E Gudjonsson; Trilokraj Tejasvi; Jingjing Yang; Vinod Chandran; Sayantan Das; Kristina Callis-Duffin; Eva Ellinghaus; Charlotta Enerbäck; Tõnu Esko; Andre Franke; Hyun M Kang; Gerald G Krueger; Henry W Lim; Proton Rahman; Cheryl F Rosen; Stephan Weidinger; Michael Weichenthal; Xiaoquan Wen; John J Voorhees; Gonçalo R Abecasis; Dafna D Gladman; Rajan P Nair; James T Elder; Lam C Tsoi
Journal:  Nat Commun       Date:  2018-10-09       Impact factor: 14.919

8.  EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update.

Authors:  Laure Gossec; Xenofon Baraliakos; Andreas Kerschbaumer; Maarten de Wit; Iain McInnes; Maxime Dougados; Jette Primdahl; Dennis G McGonagle; Daniel Aletaha; Andra Balanescu; Peter V Balint; Heidi Bertheussen; Wolf-Henning Boehncke; Gerd R Burmester; Juan D Canete; Nemanja S Damjanov; Tue Wenzel Kragstrup; Tore K Kvien; Robert B M Landewé; Rik Jozef Urbain Lories; Helena Marzo-Ortega; Denis Poddubnyy; Santiago Andres Rodrigues Manica; Georg Schett; Douglas J Veale; Filip E Van den Bosch; Désirée van der Heijde; Josef S Smolen
Journal:  Ann Rheum Dis       Date:  2020-06       Impact factor: 27.973

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.